Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of January 31st, 2025

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

18,631,386

Number of real voting rights* (excluding treasury shares**)

18,567,201

Theoretical number of voting rights* (including treasury shares**)

18,608,186

(*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF’s General Regulations

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211459162/en/

Median Technologies Emmanuelle Leygues VP, Corporate Marketing & Financial Communications [phone] [e-mail]

Press - ALIZE RP Caroline Carmagnol [phone] [e-mail]

Investors - ACTIFIN Ghislaine Gasparetto [phone] [e-mail]